"Mad Money" host Jim Cramer made calls on stocks viewers asked about.» Read More
Nov 19- An experimental drug to treat Morquio A Syndrome, a rare genetic disorder that causes skeletal malformation and a variety of related lung, eye, ear and heart problems, should be approved, an advisory panel to the U.S. Food and Drug Administration concluded on Tuesday.
The panel voted overwhelmingly that the U.S. Food and Drug Administration should approve the drug, Vimizim, which is made by BioMarin Pharmaceutical Inc. The FDA is not obliged to follow the recommendations of its advisory panels but typically does so.
The panel recommended that the U.S. Food and Drug Administration approve the drug, Vimizim, which is made by BioMarin Pharmaceutical Inc. The FDA is not obliged to follow the recommendations of its advisory panels but typically does so.
The FDA review was posted on the agency's website on Thursday ahead of a meeting of outside advisers to the agency scheduled for Nov. 19. The FDA is not bound to follow the advice of its advisory panels but typically does so. The FDA review said the main safety concerns on Vimizim relate to anaphylaxis and allergic reactions.
Nov 15- An experimental drug to treat a rare genetic disorder that causes skeletal malformation and a host of related lung, eye ear and heart problems confers "modest" benefit, according to an initial review by the U.S. Food and Drug Administration.
Pharmaceutical and biotech stocks have outperformed markets this year, and with J&J's second-quarter earnings beat, investors may hope earnings will push stocks even higher.
NEW YORK/ LOS ANGELES, July 12- Swiss drugmaker Roche Holding AG is seeking financing for a potential bid for Alexion Pharmaceuticals Inc, a transaction that if successful would be the largest healthcare deal of the year, two people familiar with the matter said on Friday.
The trick to successful investing is knowing when to take profits and walk away. In this case, Cramer says it’s time.
The "Fast Money" traders share their final trades of the day.
The spotlight at this year's American Society of Clinical Oncologists meeting will be on data from Bristol-Myers Squibb, Roche, and Merck on a new class of cancer drugs.
The ASCO meeting scheduled to begin on May 31st could generate a cornucopia of health care catalysts, said Jim Cramer.
Looking for a small stock with big return potential? Jim Cramer thinks you should consider this.
Had you picked stocks thoughtfully and carefully since Mad Money began, you would have beaten the S&P by 3000%!
The "Mad Money" host comments on viewers' favorite stocks!
These four biotech stocks could take a big hit when investors start to focus on lower-valued stocks in other industries. TheStreet.com reports.
The big U.S. and European drug companies are dealing with their own 'cliff' as blockbuster drugs lose their patent protection. But they are turning back to research and development to fill the gap.
Jim Cramer’s researcher Nicole Urken reviews the potential biotech pipeline winners there were highlighted this week on Mad Money.
The iShare Biotech ETF is up 32 percent over the past year. Jean-Jacques Bienaime, BioMarin Pharmaceutical CEO, discusses the reason behind his company behind up 24.9 percent in the last 3 months.
Strong fundamentals and dominant market positions make three biotech/pharma names stand out, Barbara Ryan says.
TheStreet.com offers up 13 biotech predictions for 2013.